Thiele Orberg, Erik http://orcid.org/0000-0003-1969-8261
Meedt, Elisabeth
Hiergeist, Andreas
Xue, Jinling
Heinrich, Paul http://orcid.org/0000-0002-6149-2083
Ru, Jinlong
Ghimire, Sakhila
Miltiadous, Oriana http://orcid.org/0000-0002-1571-3893
Lindner, Sarah
Tiefgraber, Melanie
Göldel, Sophia
Eismann, Tina
Schwarz, Alix
Göttert, Sascha
Jarosch, Sebastian http://orcid.org/0000-0002-2908-8590
Steiger, Katja http://orcid.org/0000-0002-7269-5433
Schulz, Christian
Gigl, Michael http://orcid.org/0000-0002-5617-9236
Fischer, Julius C. http://orcid.org/0000-0002-6951-3416
Janssen, Klaus-Peter http://orcid.org/0000-0002-4707-7887
Quante, Michael
Heidegger, Simon http://orcid.org/0000-0001-6394-5130
Herhaus, Peter
Verbeek, Mareike
Ruland, Jürgen http://orcid.org/0000-0002-8381-3597
van den Brink, Marcel R. M. http://orcid.org/0000-0003-0696-4401
Weber, Daniela
Edinger, Matthias
Wolff, Daniel http://orcid.org/0000-0001-7015-3190
Busch, Dirk H. http://orcid.org/0000-0001-8713-093X
Kleigrewe, Karin http://orcid.org/0000-0002-7718-0252
Herr, Wolfgang
Bassermann, Florian http://orcid.org/0000-0003-4435-2609
Gessner, André
Deng, Li
Holler, Ernst
Poeck, Hendrik http://orcid.org/0000-0002-0836-2095
Article History
Received: 8 March 2023
Accepted: 13 October 2023
First Online: 3 January 2024
Competing interests
: E.T.O.: honoraria (BeiGene), travel (BeiGene). M.R.M.v.d.B.: research support and stock options from Seres Therapeutics and stock options from Notch Therapeutics and Pluto Therapeutics; he has received royalties from Wolters Kluwer; he has consulted, received honorarium from or participated in advisory boards for Seres Therapeutics, Vor Biopharma, Rheos Medicines, Frazier Healthcare Partners, Nektar Therapeutics, Notch Therapeutics, Ceramedix, LyGenesis, Pluto Therapeutics, GlaxoSmithKline, Da Volterra, Thymofox, Garuda, Novartis (spouse), Synthekine (spouse), BeiGene (spouse), Kite (spouse); he has IP licensing with Seres Therapeutics and Juno Therapeutics; and he holds a fiduciary role on the foundation board of DKMS (a nonprofit organization). E.H.: scientific advisory board (MaaT Pharma, PharmaBiome (Novartis–Medac)), honoraria and research funding (Neovii, Novartis and Medac). H.P.: honoraria (Novartis, Gilead–Kite, AbbVie, Pfizer, MSD, Bristol Myers Squibb (BMS), Servier, Janssen-Cilag), travel (Janssen-Cilag, Novartis, AbbVie, Novartis, Jazz, Gilead–Kite, AMGEN), research (BMS). C.S.: honoraria (Lilly, Tillotts, Juvisé), research (Luvos). S.H. has been a consultant for BMS, Novartis, Merck, AbbVie and Roche; has received research funding from BMS and Novartis; and is an employee of and holds equity interest in Roche–Genentech. M.V.: honoraria from Novartis, Medac, AbbVie and Jazz Pharmaceuticals as well as travel grants from Medac, Gilead and Jazz Pharmaceuticals. A.S.: honoraria (BeiGene), travel (BeiGene). W.H.: honoraria (Amgen, Novartis), travel (Amgen, Janssen-Cilag). The remaining authors declare no competing interests.